Drug manufacturer AstraZeneca and the federal government are miles apart on what a federal judge should do next after ruling last week that the government had no basis for stating in December that the 340B statute unambiguously requires manufacturers to honor 340B contract pharmacy arrangements.
U.S. Chief Judge Leonard Stark of the District of Delaware ruled on June 16 Congress was silent about the role that contract pharmacies may play in purchases of 340B drugs, and “there is more than one permissible interpretation of the statute.” He ordered the two sides to report to him by yesterday on what relief AstraZeneca is entitled to in light of his ruling, and how the case should proceed, if at all.
Drug manufacturer AstraZeneca and the federal government are miles apart on what a federal judge should do next after ruling last week that the government had no basis for stating in December that the 340B statute unambiguously requires manufacturers to honor 340B contract pharmacy arrangements.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
